Empowering Patients to Make Informed Treatment Decisions in ADHD: What They Need to KnowPremiere Date: Monday, January 31, 2022
This activity offers CE credit for:%>
- ABIM (MOC)
- Medicine (accme)
- Nursing (ANCC)
- Pharmacy (acpe)
- PA (aapa)
All other clinicians will receive a Certificate of Attendance stating this activity was certified for AMA PRA Category 1 Credit™
Credit Expiration Date:
Tuesday, January 31, 2023
Note: Credit Is No Longer Available
|Ann Childress, MD (Moderator)
President, Center for Psychiatry and Behavioral Medicine, Inc.
Associate Professor Child/Adolescent Psychiatry
Touro University Nevada College of Osteopathic Medicine
Clinical Associate Professor
University of Nevada, Las Vegas School of Medicine
Las Vegas, NV
|Scott H. Kollins, PhD
Chief Medical Officer, Holmusk
Adjunct Professor of Psychiatry and Behavioral Science
Duke University School of Medicine
Parents and caregivers of children with attention-deficit/hyperactivity disorder (ADHD), as well as adults with this condition, often indicate limited knowledge of the available therapies for ADHD, particularly pharmacotherapies for which they often express concern about diversion or addiction. However, providing parents, caregivers, and patients with detailed information can mitigate those concerns and enable them to be active participants in treatment planning. Likewise, as treatment nonadherence is common in ADHD management, it is imperative to educate parents, caregivers, and patients about its negative impact on psychosocial functioning and quality of life.
For insight on ADHD medication profiles, behavioral therapies, and supportive strategies to enhance treatment adherence, join our faculty experts for this fourth installment in the CME Outfitters series “ADHD Can Be a Moving Target: Equip Yourself with the Tools to Detect and Manage ADHD to Reduce Its Burden.”
At the end of this CE activity, participants should be able to:
- Educate patients and caregivers about the available ADHD medication profiles, behavioral therapies, and significance of adherence to therapy.
Supported by an educational grant from Takeda Pharmaceuticals U.S.A., Inc.
Physicians, PAs, nurse practitioners, nurses, and pharmacists specializing in psychiatry and/or pediatrics
ABIM MOC Credit:
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.5 medical knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
Royal College MOC:
Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.
MIPS Improvement Activity:
This activity counts towards MIPS Improvement Activity requirements under the Medicare Access and CHIP Reauthorization Act of 2015 (MACRA). Clinicians should submit their improvement activities by attestation via the CMS Quality Payment Program website.
It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CME Outfitters, LLC, has evaluated, identified, and attempted to resolve any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.
Dr. Childress reports the following financial relationships:
Consultant: : Aardvark Therapeutics, Inc.; Corium Inc.; Jazz Pharmaceuticals, Inc.; KemPharm, Inc.; Lumos Pharma; Neos Therapeutics, Inc.; Noven Pharmaceuticals, Inc.; Sunovion Pharmaceuticals Inc.; Supernus Pharmaceuticals, Inc.; and Tulex Pharmaceuticals
Research Support: : Adlon Therapeutics L.P.; Akili Interactive Labs, Inc.; Allergan; Arbor Pharmaceuticals; KemPharm, Inc.; Neos Therapeutics, Inc.; Otsuka America Pharmaceutical, Inc.; Purdue Pharma L.P.; Sunovion Pharmaceuticals Inc.; Supernus Pharmaceuticals, Inc.; Takeda Pharmaceuticals U.S.A., Inc.; and Tris Pharma, Inc.
Speakers Bureau: Corium Inc.; Ironshore Pharmaceuticals Inc.; Supernus Pharmaceuticals, Inc.; Takeda Pharmaceuticals U.S.A., Inc.; and Tris Pharma, Inc.
Other Financial or Material Support: Writing support for Purdue Pharma L.P.; Supernus Pharmaceuticals, Inc.; and Takeda Pharmaceuticals U.S.A., Inc.
Dr. Kollins reports the following financial relationships:
Consultant: Akili Interactive Labs, Inc.; Lumos Labs, Inc.
Other Financial or Material Support: Full-time employee of Holmusk
Stock Shareholder (ownership interest): Akili Interactive Labs, Inc.; Holmusk
The following Peer Reviewer and CME Outfitters staff have no financial relationships to disclose:
Faculty of this CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.
Questions about this activity? Call us at 877.CME.PROS (877.263.7767).